Study of Myocardial Perfusion by MRI
Magnetic resonance imaging
Aortic Valve Disease+14
+ Aortic Stenosis, Subvalvular
+ Aortic Valve Stenosis
Treatment Study
Summary
Study start date: August 1, 1997
Actual date on which the first participant was enrolled.In this pilot study, magnetic resonance imaging (MRI) of myocardial enhancement during first passage of intravenously injected gadolinium contrast will be used to evaluate regional myocardial perfusion in patients with known or suspected coronary artery disease and hypertrophic cardiomyopathy. The MRI results will be compared with conventional radionuclide perfusion studies (ex. dipyridamole thallium). A clinically defined normal group will also be studied without radionuclide correlation.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.249 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
INCLUSION CRITERIA: Ages 18 to 80. Either sex. Capable of giving informed consent. Group 1: Outpatients with known or suspected coronary artery disease with clinical indication for radionuclide perfusion imaging. Group 2: Patients with non-obstructive hypertrophic cardiomyopathy with clinical indication for radionuclide perfusion imaging. Group 3: Normal volunteers. Positive stress thallium or stress sestamibi (i.e., exercise, adenosine, dobutamine or dypiridamole) at the NIH. EXCLUSION CRITERIA: Pregnancy. Unstable angina. Uncontrolled hypertension (SBP greater than 185, DBP greater than 105). Recent myocardial infarction (less than 5 days). 2nd or 3rd degree heart block by ECG. Asthma, emphysema, renal failure, acute medical illness (fever, pneumonia, etc.) or anemia (hct less than 30). Cardiac pacemaker or implantable defibrillator, aneurysm clip, neural stimulator, any type of ear implant, metal in your eye, any implanted device (i.e. insulin pump, drug infusion device) or any metallic foreign body, shrapnel, or bullet.
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, United StatesOpen National Heart, Lung and Blood Institute (NHLBI) in Google Maps